Top

BMC Cancer

Published in:

01-12-2021 | Mastectomy | Research

Local treatment for triple-negative breast cancer patients undergoing chemotherapy: breast-conserving surgery or total mastectomy?

Authors: Leqian Guo, Guilan Xie, Ruiqi Wang, Liren Yang, Landi Sun, Mengmeng Xu, Wenfang Yang, Mei Chun Chung

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Because there is no exact therapeutic target, the systemic treatment of triple-negative breast cancer (TNBC) still relies on chemotherapy. In terms of local treatment, based on the highly malignant characteristics of TNBC, it is still uncertain whether patients should be given more aggressive local treatment.

Methods

This study was based on the SEER database. 13,262 TNBC patients undergoing chemotherapy were included. According to local treatment methods, patients were divided into breast-conserving surgery with radiotherapy (BCS + RT), total mastectomy alone and total mastectomy with radiotherapy (Mastectomy+RT). Kaplan-Meier survival analysis drew the survival curves of Overall Survival (OS) and Breast Cancer Specific Survival (BCSS), and Cox proportional risk regression models were used to analyze the impact of different local treatments on OS and BCSS.

Results

After adjusting confounding factors, Mastectomy alone group (HR = 1.57; 95%CI: 1.40–1.77) and Mastectomy+RT group (HR = 1.28; 95%CI: 1.12–1.46) were worse in OS than BCS + RT group, and Mastectomy+RT group (HR = 0.81; 95%CI: 0.73–0.91) was better in OS than Mastectomy alone group. The effect of local treatment for BCSS was similar to that of OS. After stratification according to age, tumor size and lymph node status, when the age was less than 55 years old, at T4, N2 or N3 category, there was no statistical significance between the BCS + RT group and the Mastectomy+RT group in OS or BCSS (all P > 0.05). When the age was less than 65 years old, at T1, T2 or N0 category, there was no statistical significance between the Mastectomy alone group and the Mastectomy+RT group in OS or BCSS (all P > 0.05). The results of other stratified analyses were basically consistent with the results of total population analysis.

Conclusion

The survival benefit of breast-conserving surgery with radiotherapy was higher than or similar to that of total mastectomy TNBC patients.

Latest global cancer data: Cancer burden rises to 19.3 million new cases and 10.0 million cancer deaths in 2020 [https://www.iarc.who.int/news-events/latest-global-cancer-data-cancer-burden-rises-to-19-3-million-new-cases-and-10-0-million-cancer-deaths-in-2020/]. Accessed 15 Mar 2021.

Ismail-Khan R, Bui MM. A review of triple-negative breast cancer. Cancer Control. 2010;17(3):173–6. https://doi.org/10.1177/107327481001700305.CrossRefPubMed

Zardavas D, Irrthum A, Swanton C, Piccart M. Clinical management of breast cancer heterogeneity. Nat Rev Clin Oncol. 2015;12(7):381–94. https://doi.org/10.1038/nrclinonc.2015.73.CrossRefPubMed

Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, et al. Refinement of triple-negative breast Cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS One. 2016;11(6):e0157368. https://doi.org/10.1371/journal.pone.0157368.CrossRefPubMedPubMedCentral

Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol. 2012;23(Suppl 6):vi7–12.CrossRefPubMed

Handa T, Katayama A, Yokobori T, Yamane A, Horiguchi J, Kawabata-Iwakawa R, et al. Caspase14 expression is associated with triple negative phenotypes and cancer stem cell marker expression in breast cancer patients. J Surg Oncol. 2017;116(6):706–15. https://doi.org/10.1002/jso.24705.CrossRefPubMed

Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT trial. Nat Med. 2018;24(5):628–37. https://doi.org/10.1038/s41591-018-0009-7.CrossRefPubMedPubMedCentral

Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the national comprehensive Cancer network. Cancer. 2012;118(22):5463–72. https://doi.org/10.1002/cncr.27581.CrossRefPubMed

Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. New Engl J Med. 2010;363(20):1938–48. https://doi.org/10.1056/NEJMra1001389.CrossRefPubMed

10.

NCCN guideline for treatment of breast cancer [https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf]. Accessed 15 Mar 2021.

11.

Simone NL, Dan T, Shih J, Smith SL, Sciuto L, Lita E, et al. Twenty-five year results of the national cancer institute randomized breast conservation trial. Breast Cancer Res Treat. 2012;132(1):197–203. https://doi.org/10.1007/s10549-011-1867-6.CrossRefPubMed

12.

Agarwal S, Pappas L, Neumayer L, Kokeny K, Agarwal J. Effect of breast conservation therapy vs mastectomy on disease-specific survival for early-stage breast cancer. JAMA Surg. 2014;149(3):267–74. https://doi.org/10.1001/jamasurg.2013.3049.CrossRefPubMed

13.

van Maaren MC, de Munck L, de Bock GH, Jobsen JJ, van Dalen T, Linn SC, et al. 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study. Lancet Oncol. 2016;17(8):1158–70. https://doi.org/10.1016/S1470-2045(16)30067-5.CrossRefPubMed

14.

Zumsteg ZS, Morrow M, Arnold B, Zheng J, Zhang Z, Robson M, et al. Breast-conserving therapy achieves locoregional outcomes comparable to mastectomy in women with T1-2N0 triple-negative breast cancer. Ann Surg Oncol. 2013;20(11):3469–76. https://doi.org/10.1245/s10434-013-3011-9.CrossRefPubMedPubMedCentral

15.

Abdulkarim BS, Cuartero J, Hanson J, Deschênes J, Lesniak D, Sabri S. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol. 2011;29(21):2852–8. https://doi.org/10.1200/JCO.2010.33.4714.CrossRefPubMedPubMedCentral

16.

Khalifa J, Duprez-Paumier R, Filleron T, Lacroix Triki M, Jouve E, Dalenc F, et al. Outcome of pN0 triple-negative breast Cancer with or without lymph node irradiation: a single institution experience. Breast J. 2016;22(5):510–9. https://doi.org/10.1111/tbj.12626.CrossRefPubMed

17.

Yi JC, Syrjala KL. Anxiety and depression in Cancer survivors. Med Clin North Am. 2017;101(6):1099–113. https://doi.org/10.1016/j.mcna.2017.06.005.CrossRefPubMedPubMedCentral

18.

Chen SS, Tang SC, Li K, Wu J, Li X, Ren H, et al. Predicting the survival of triple-negative breast Cancer in different stages: a SEER population based research referring to Clinicopathological factors. Cancer Investig. 2020:1–10.

19.

Dai D, Jin H, Wang X. Nomogram for predicting survival in triple-negative breast cancer patients with histology of infiltrating duct carcinoma: a population-based study. Am J Cancer Res. 2018;8(8):1576–85.PubMedPubMedCentral

20.

Luo J, Kroenke CH, Hendryx M, Shadyab AH, Liu N, Chen X, et al. Mediation analysis of racial disparities in triple-negative breast cancer incidence among postmenopausal women. Breast Cancer Res Treat. 2021.

21.

Wang F, Zheng W, Bailey CE, Mayer IA, Pietenpol JA, Shu XO. Racial/ethnic disparities in all-cause mortality among patients diagnosed with triple-negative breast Cancer. Cancer Res. 2021;81(4):1163–70. https://doi.org/10.1158/0008-5472.CAN-20-3094.CrossRefPubMed

22.

Collins LC, Marotti JD, Gelber S, Cole K, Ruddy K, Kereakoglow S, et al. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat. 2012;131(3):1061–6. https://doi.org/10.1007/s10549-011-1872-9.CrossRefPubMed

23.

Alcantara VS, Lim GH, Lim SH, Sultana R, Lee JA. Incidence and prognosis of non-metastatic triple negative breast cancer (TNBC) among different races in Southeast Asia. J Surg Oncol. 2017;115(5):523–37. https://doi.org/10.1002/jso.24559.CrossRefPubMed

24.

He MY, Rancoule C, Rehailia-Blanchard A, Espenel S, Trone JC, Bernichon E, et al. Radiotherapy in triple-negative breast cancer: current situation and upcoming strategies. Crit Rev Oncol Hematol. 2018;131:96–101. https://doi.org/10.1016/j.critrevonc.2018.09.004.CrossRefPubMed

25.

Vila J, Gandini S, Gentilini O. Overall survival according to type of surgery in young (</=40 years) early breast cancer patients: a systematic meta-analysis comparing breast-conserving surgery versus mastectomy. Breast. 2015;24(3):175–81. https://doi.org/10.1016/j.breast.2015.02.002.CrossRefPubMed

26.

Bhoo-Pathy N, Verkooijen HM, Wong FY, Pignol JP, Kwong A, Tan EY, et al. Prognostic role of adjuvant radiotherapy in triple-negative breast cancer: a historical cohort study. Int J Cancer. 2015;137(10):2504–12. https://doi.org/10.1002/ijc.29617.CrossRefPubMed

27.

Newman LA, Kaljee LM. Health disparities and triple-negative breast Cancer in African American women: a review. JAMA Surg. 2017;152(5):485–93. https://doi.org/10.1001/jamasurg.2017.0005.CrossRefPubMed

28.

Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. Int J Radiat Oncol Biol Phys. 2014;88(3):553–64. https://doi.org/10.1016/j.ijrobp.2013.11.012.CrossRefPubMedPubMedCentral

29.

Jiang YZ, Ma D, Suo C, Shi J, Xue M, Hu X, Xiao Y, Yu KD, Liu YR, Yu Y et al. Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell. 2019;35(3):428–40.e5.

30.

Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020;396(10257):1090–100. https://doi.org/10.1016/S0140-6736(20)31953-X.CrossRefPubMed

31.

Denkert C, Liedtke C, Tutt A, von Minckwitz G. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2017;389(10087):2430–42. https://doi.org/10.1016/S0140-6736(16)32454-0.CrossRefPubMed

32.

Li S, Li L, Zheng H, Wang Y, Zhu X, Yang Y, et al. Relationship between multifaceted body image and negative affect among women undergoing mastectomy for breast cancer: a longitudinal study. Arch Womens Ment Health. 2018;21(6):681–8. https://doi.org/10.1007/s00737-018-0860-z.CrossRefPubMed

33.

Prat A, Lluch A, Albanell J, Barry WT, Fan C, Chacon JI, et al. Predicting response and survival in chemotherapy-treated triple-negative breast cancer. Br J Cancer. 2014;111(8):1532–41. https://doi.org/10.1038/bjc.2014.444.CrossRefPubMedPubMedCentral

34.

Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674–90. https://doi.org/10.1038/nrclinonc.2016.66.CrossRefPubMedPubMedCentral

Title: Local treatment for triple-negative breast cancer patients undergoing chemotherapy: breast-conserving surgery or total mastectomy?
Authors: Leqian Guo
Guilan Xie
Ruiqi Wang
Liren Yang
Landi Sun
Mengmeng Xu
Wenfang Yang
Mei Chun Chung
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Mastectomy
Breast Cancer
Breast Cancer
Radiotherapy
Cytostatic Therapy
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08429-9

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Image Credits

ASCO 2024 | Highlights of the Day: Breast cancer – metastatic/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Gynecologic Cancer/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Breast Cancer – local/regional/adjuvant/© 2024 American Society of Clinical Oncology, all rights reserved., Melanoma/© selvanegra / Getty Images / iStock, Antibody drug conjugated with cytotoxic payload/© Love Employee / Getty images / iStock

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

The combination of 13N-ammonia and 11C-methionine in differentiation of residual/recurrent pituitary adenoma from the pituitary gland remnant after trans-sphenoidal Adenomectomy

Nomogram based on autophagy related genes for predicting the survival in melanoma

Downregulation of CCL22 and mutated NOTCH1 in tongue and mouth floor squamous cell carcinoma results in decreased Th2 cell recruitment and expression, predicting poor clinical outcome

Knowledge of a cancer diagnosis is a protective factor for the survival of patients with breast cancer: a retrospective cohort study

Colorectal cancer incidence and mortality trends by sex and population group in South Africa: 2002–2014

Recurrent KRAS, KIT and SF3B1 mutations in melanoma of the female genital tract